RESEARCH ARTICLE Open Access
Reduced immunomodulation potential of bone
marrow-derived mesenchymal stem cells induced
CCR4+
CCR6+
Th/Treg cell subset imbalance in
ankylosing spondylitis
Yanfeng Wu1†
, Mingliang Ren2†
, Rui Yang2
, Xinjun Liang2
, Yuanchen Ma3
, Yong Tang2
, Lin Huang2
, Jichao Ye2
,
Keng Chen2
, Peng Wang2*
, Huiyong Shen2*
Abstract
Introduction: Ankylosing spondylitis (AS) is a chronic autoimmune disease, and the precise pathogenesis is largely
unknown at present. Bone marrow-derived mesenchymal stem cells (BMSCs) with immunosuppressive and anti-
inflammatory potential and Th17/Treg cells with a reciprocal relationship regulated by BMSCs have been reported
to be involved in some autoimmune disorders. Here we studied the biological and immunological characteristics
of BMSCs, the frequency and phenotype of CCR4+
CCR6+
Th/Treg cells and their interaction in vitro in AS.
Methods: The biological and immunomodulation characteristics of BMSCs were examined by induced multiple-
differentiation and two-way mixed peripheral blood mononuclear cell (PBMC) reactions or after stimulation with
phytohemagglutinin, respectively. The interactions of BMSCs and PBMCs were detected with a direct-contact co-
culturing system. CCR4+
CCR6+
Th/Treg cells and surface markers of BMSCs were assayed using flow cytometry.
Results: The AS-BMSCs at active stage showed normal proliferation, cell viability, surface markers and multiple
differentiation characteristics, but significantly reduced immunomodulation potential (decreased 68 ± 14%); the
frequencies of Treg and Fox-P3+
cells in AS-PBMCs decreased, while CCR4+
CCR6+
Th cells increased, compared
with healthy donors. Moreover, the AS-BMSCs induced imbalance in the ratio of CCR4+
CCR6+
Th/Treg cells by
reducing Treg/PBMCs and increasing CCR4+
CCR6+
Th/PBMCs, and also reduced Fox-P3+
cells when co-cultured
with PBMCs. Correlation analysis showed that the immunomodulation potential of BMSCs has significant negative
correlations with the ratio of CCR4+
CCR6+
Th to Treg cells in peripheral blood.
Conclusions: The immunomodulation potential of BMSCs is reduced and the ratio of CCR4+
CCR6+
Th/Treg cells is
imbalanced in AS. The BMSCs with reduced immunomodulation potential may play a novel role in AS
pathogenesis by inducing CCR4+
CCR6+
Th/Treg cell imbalance.
Introduction
Ankylosing spondylitis (AS) is a chronic autoimmune
inflammatory disease, the prototypic seronegative spon-
dylarthritis that primarily affects the sacroiliac joints and
the axial skeleton, which was characterized by inflamma-
tory back pain, enthesitis, and specific organ involve-
ment [1]. AS is a complex multifactorial disease; several
pathogenetic factors, including infection [1,2], environ-
mental triggers [1], genetic susceptibility such as HLA-
B27 positivity [3,4] and HLA-E gene polymorphism [5],
and in particular, autoimmune disorders [1] have been
reported to potentially trigger the onset or maintain the
pathogenesis progress of AS. Additionally, the genome-
wide association study of AS identifies non-MHC sus-
ceptibility loci [6], such as IL-23R (rs11209026) and
ERAP1 (rs27434). There were also, however, some con-
troversies; for example, no candidate bacteria were
detected by PCR in biopsies from sacroiliac joints [7]
* Correspondence: sunfox809@yahoo.com.cn; shenhuiyong@yahoo.com.cn
† Contributed equally
2
Biotherapy Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
107# Yanjiangxi Road, Guangzhou 510120, PR China
Full list of author information is available at the end of the article
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
© 2011 Wu et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
and most HLA B27-positive individuals remain healthy
[1]. The precise pathogenesis of AS is therefore largely
unknown at present. Nowadays, more and more studies
have focused on the immunological factors for AS.
Mesenchymal stromal cells (MSCs) isolated from a
variety of adult tissues, including the bone marrow, have
multiple differentiation potentials in different cell types,
and also display immunosuppressive (in vitro [8,9], in
vivo [10-12]) and anti-inflammatory properties [13], so
their putative therapeutic role in a variety of inflamma-
tory autoimmune diseases is currently under investiga-
tion. Recently, many findings indicate that MSC
immunomodulation potential plays a critical role in
severe aplastic anemia [14]. Simultaneously, substantial
disorders and abnormalities of MSCs exist in many
autoimmune diseases [15]. Few studies, however, have
so far focused on whether there were some abnormal-
ities in bone marrow-derived mesenchymal stem cells
(BMSCs) of patients with ankylosing spondylitis
(ASp) with regard to the biological and immunological
properties.
More recently, two additional subsets, the forkhead
box P3 (Fox-P3)-positive regulatory subset (Treg) and
the IL-17-producing subset (Th17) [16-19], have
emerged and together with Th1 and Th2 cells, formed a
functional quartet of CD4+
T cells that provides a closer
insight into the mechanisms of immune-mediated dis-
eases such as AS. Autoimmune diseases are thought to
arise from a breakdown of immunological self-tolerance
leading to aberrant immune responses to self-antigen.
Ordinarily, regulatory T (Treg) cells - including both
natural and induced Treg cells - control these self-reac-
tive cells [20]. Several studies of patients with connective
tissue diseases found reduced [21] or functionally
impaired [22] Treg cells, and Treg cells of autoimmune
hepatitis patients have reduced expression of Fox-P3
and CTLA-4, which may lead to impaired suppressor
activity [23]. On the contrary, these proinflammatory
Th17 cells are implicated in different autoimmune dis-
ease models [24-26]. Furthermore, these cells typically
express IL-23R on their membrane [27], and recent stu-
dies in AS [28-30] show an important genetic contribu-
tion for polymorphisms in the gene that codes for this
IL-23R. The active polymorphisms in the IL-23R
gene could thus indicate an important role for this
pathogenic T-cell subset (Th17) in the development
and maintenance of AS. The involvement of Treg and
Th17 cells in AS, however, has not yet been clearly
established.
As previously described, skewing of responses towards
Th17 and away from BMSCs or Treg cells may be
responsible for the development and/or progression of
AS [31]. Furthermore, CCR6 and CCR4 identified true
Th17 memory cells producing IL-17 [32] and the
majority of Th17 cells were CCR6+
CCR4+
[33]. Aimed
at investigating the puzzling issues above, the present
study was designed to examine the biological and
immunological properties of BMSCs, to examine the fre-
quencies and phenotypes of Treg cells and proinflam-
matory CCR4+
CCR6+
Th memory cells, and to study
the interactions between BMSCs and CCR4+
CCR6+
Th/Treg cells in peripheral blood mononuclear cells
(PBMCs) for AS.
Materials and methods
Patients and controls
The present study was approved by the ethics commit-
tee of the Sun Yat-Sen Memorial Hospital of Sun
Yat-Sen University, Guangzhou, China. In addition,
informed consent was obtained from all patients and all
healthy donors (HDs). Fifty-one ASp (eight women and
43 men) with an average age of 29.4 years (17 to 45
years) and 49 HDs (eight women and 41 men) with an
average age of 27.3 years (18 to 39 years) were included
in the study. All of the AS patients were diagnosed
according to the New York modified criteria [34] and
were HLA-B27-positive; conversely, 37 healthy donors
were HLA-B27-negative (HD1) and 12 healthy donors
were HLA-B27-positive (HD2). Sixteen patients were
diagnosed for the first time, and the research samples
from all ASp were taken at the active stage (all Bath
Ankylosing Spondylitis Disease Activity Index ≥4) and
without taking any medicine for at least 2 weeks.
Bone marrow aspiration, human BMSCs and PBMCs
After being informed regarding the scientific contribu-
tions, possible risks and complications and the corre-
sponding prevention and treating measures for bone
marrow aspirations, all of the healthy controls and ASp
expressed approval and signed the informed consent.
The bone marrow aspirations were all performed by
skilled allied health professionals strictly according to
the international standardized procedure for bone mar-
row aspirations. The bone marrow samples of AS
patients and HDs were diluted with DMEM (low-glu-
cose DMEM) containing 10% FBS. The mononuclear
cells were prepared by gradient centrifugation at 900 × g
for 30 minutes on Percoll (Pharmacia Biotech, Uppsala,
Sweden) of density 1.073 g/ml. The cells were washed,
counted, seeded at 2 × 106
cells/cm2
in 25-cm2
flasks
containing low-glucose DMEM supplemented with 10%
FBS and cultured at 37°C, 5% carbon dioxide. Medium
was replaced and the cells in suspension were removed
at 48 hours and every 3 or 4 days thereafter. BMSCs
were recovered using 0.25% Trypsin-ethylenediamine
tetraacetic acid and replated at a density of 5 × 103
to
6 × 103
cells/cm2
surface area as passage 1 cells when
the culture reached 90% confluency. BMSCs after the
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 2 of 15
third subculture were used for described experiments.
PBMCs were obtained by the Ficoll-Hypaque (Pharma-
cia Biotech, Uppsala, Sweden) gradient separation of the
buffy coat of ASp and HDs.
Cell viability and proliferation test for BMSCs
BMSCs were seeded in 96-well plates at a concentration
of 1 × 104
/ml, in a final volume of 100 μl fresh medium
(10% FBS + low-glucose DMEM), and three wells of
each sample were digested using 0.25% Trypsin-ethyle-
nediamine tetraacetic acid for cell counting per day up
to 12 days. The BMSC growth curves were made using
the data for cell proliferation obtained above. Using
MTT (5 mg/ml; Sigma-Aldrich Co., St. Louis, MO,
USA), dimethyl sulphoxide (Sigma) and an EL800
microplate reader (BioTek Instruments, Winooski, VT,
USA) that was to determine absorbance at 490 nm, the
cell viability curves for BMSCs were acquired in the
same way according to the day and the absorbance.
The BMSC proliferation ability was also examined by
3
H-TdR assay. Fresh medium was used as a negative
control.
In vitro differentiation potential assay of BMSCs
To induce osteogenic differentiation, BMSCs were initi-
ally seeded in six-well plates at a concentration of 104
/
cm2
. After preculturing for 24 hours, the BMSCs were
allowed to grow in osteogenic medium (high-glucose
DMEM supplemented with 10% FBS, 50 mg/l ascorbic
acid, 10 mM b-glycerolphosphate and 10 nM dexa-
methasone; all these inducing reagents from Sigma).
The BMSCs were then incubated in 5% carbon dioxide
at 37°C, according to the experimental requirements for
up to 14 days, and the medium was replaced every 3
days before harvest. The alkaline phosphatase (ALP) and
mineralization of BMSCs were assayed using Cell Alka-
line Phosphatase Staining assay (Sigma) and Alizarin
Red staining (AR-S, 40 mmol/l, pH 4.2; Sigma) on the
14th day, respectively.
To induce adipogenic differentiation, the BMSCs were
seeded in six-well plates at a concentration of 104
/cm2
.
After preculturing for 24 hours, the BMSCs were shifted
to adipogenic medium (low-glucose DMEM supplemen-
ted with 10% FBS, 1 μM dexamethasone, 10 μg/ml insu-
lin, 0.5 mM 3-isobutyl-1-methylxanthine and 0.2 mM
indomethacin; all these inducing reagents from Sigma).
The BMSCs were then incubated in 5% carbon dioxide
at 37°C, and the medium was replaced every 3 days
before harvest. The intracellular lipid accumulation as
an indicator was visualized on the 14th day by Oil Red
O staining after fixed with 4% cold paraformaldehyde in
PBS (pH 7.4) and washed with distilled water.
To induce chondrogenic differentiation, aliquots of
2.5 × 105
BMSCs were centrifuged at 1,000 rpm for
5 minutes in 15-ml polypropylene conical tubes to form
pellets, which were then cultured in high-glucose
DMEM supplemented with 1% ITS-Premix (Becton-
Dickinson, Mountain View, CA, USA), 50 mg/ml ascor-
bic acid (Sigma), 10-3
M sodium pyruvate (Sigma), 10-7
M dexametazone (Sigma), and 10 ng/ml transforming
growth factor-b3 (R&D Systems, Minneapolis, MN,
USA) for 28 days. The pellets were then fixed with
4% paraformaldehyde, embedded in paraffin, and sub-
jected to Alcian blue staining to confirm chondrogenic
differentiation.
The BMSCs in fresh medium (high-glucose DMEM
supplemented with 10% FBS) without these differentia-
tion-inducing factors were used as the experimental
control, and fresh medium without any cells was used
as a negative control. All measurements were performed
in triplicate. The images were visualized using an
inverted phase contrast microscope (Nikon Eclipse Ti-S,
Nikon Corporation, Tokyo Prefecture, Japan).
Alkaline phosphatase measurement
On the 14th day the osteogenic medium was removed,
and then 1.0 ml Triton X-100 (Sigma) was added to
each well. A cell scraper was used to remove the
BMSCs from the well bottom, and then the 1.0 ml cell
lysate were placed in a 1.5-ml centrifuge tube. The sam-
ples were then processed through two freeze-thaw cycles
(-70°C and room temperature, 45 minutes each) to rup-
ture the cell membrane and extract the proteins and
DNA from the cells. A p-nitrophenyl phosphate liquid
substrate system (Stanbio, Boerne, TX, USA) was used
to analyze the ALP concentration from the cells of each
group. Then 10 μl each cell lysate solution was added to
190 μl p-nitrophenyl phosphate substrate and incubated
in the dark at room temperature for 1 minute. The
absorbance was read using a plate reader (M5 Spectra-
Max; Molecular Devices, Sunnyvale, CA, USA) at 405
nm and normalized to the PicoGreen assay [35]. DNA
was quantified using the Quant-iT PicoGreen Kit (Invi-
trogen, Carlsbad, CA, USA) following standard proto-
cols. Briefly, 100 μl each cell lysate solution was added
to 100 μl PicoGreen reagent and incubated in the dark
at room temperature for 5 minutes. The absorbance was
read at an excitation/emission of 480 to 520 nm on the
plate reader.
Immunomodulation potential of BMSCs
The inhibitory effects of BMSCs on mixed PBMC reac-
tion (MLR) and PBMC proliferation stimulated by phy-
tohemagglutinin (PHA) (4 μg/ml; Roche, Mannheim,
Germany) were measured using the MTT assay [36] and
the 3
H-TdR assay [10] as described previously. Briefly,
BMSCs were seeded in V-bottomed, 96-well culture
plates for 4 hours for adherence, and then irradiated
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 3 of 15
(30 Gy) with Co60
before being cultured with the mixed
PBMCs or the PBMCs stimulated by PHA.
Two-way mixed PBMC reaction
For the two-way MLR, allogeneic PBMCs (15 × 104
cells/
cm2
) from a healthy volunteer were mixed in a 1:1 ratio
with PBMCs from another unrelated healthy volunteer
(third-party setting). The mixed PBMCs were then mixed
with different amounts (15 × 103
cells/cm2
= 1:20 BMSC:
PBMC ratio, 3 × 104
cells/cm2
= 1:10, 6 × 104
cells/cm2
= 1:5, 15 × 104
cells/cm2
= 1:2, 3 × 105
cells/cm2
= 1:1)
of BMSCs (experiment wells) or without BMSCs (blank
wells) in V-bottomed, 96-well culture plates to ensure
efficient cell-cell contact for 5 days in 0.2 ml modified
RPMI-1640 medium (Gibco, BRL, Grand Island, NY,
USA) supplemented with 10% FBS.
Allogeneic PBMC proliferation assay
Compared with the MLR, the allogeneic PBMC prolif-
eration assay only uses one allogeneic PBMC reaction
(30 × 104
cells/cm2
) from a healthy volunteer stimulated
with PHA, instead of two PBMC reactions. Inhibitory
effects were measured on the 5th day using the MTT
assay with an EL800 microplate reader at 570 nm and
the 3
H-TdR assay with a microplate scintillation and
luminescence counter (Packard NXT, Meriden, CT,
USA). Results were expressed as mean absorbance (opti-
cal density (OD)) ± standard deviation (SD) and as
mean counts per minute (CPM) ± SD, respectively. All
measurements were performed in triplicate.
The data are presented as percentage inhibition values
calculated using the following formulae (Table 1):
% inhibition = 1 − (OD (exp) − OD (adj)) /OD (bla)
% inhibition = 1 − (CPM (exp) − CPM (adj)) /CPM (bla)
OD(exp), OD(adj) and OD(bla) represent the mean
absorbance of experiment wells, adjusted wells (only
BMSCs) and blank wells, respectively, and CPM(exp),
CPM(adj) and CPM(bla) represent the mean counts per
minute of the corresponding wells. Depending on the
experimental design, there were some wells used for
controlling. Results were expressed as the mean (% inhi-
bition) ± SD.
Direct contact co-culture of BMSCs and PBMCs
BMSCs were trypsinized and then irradiated (30 Gy)
with Co60
before being co-cultured with PBMCs from a
healthy volunteer in the presence of PHA (4 μg/ml;
Roche) in 24-well plates (Nunclon, Roskilde, Denmark)
and plated at a ratio of 1:10 in a total volume of 2 ml/
well in triplicate for 72 hours. The cell density was 5 ×
104
/cm2
BMSCs and 5 × 105
/cm2
PBMCs in a mix.
Phorbol myristate acetate (50 ng/ml; Sigma, St Louis,
MO, USA) and calcium ionomycin (1 μg/ml; Sigma)
were added 6 hours prior to the end of the 72-hour co-
culture. All of the PBMCs were then collected to be
assayed by flow cytometry for the CCR4+
CCR6+
Th and
Treg cells. PBMCs were also grown alone in BMSC-free
medium and used as control.
Antibodies and flow cytometry
To detect the surface markers [37] of BMSCs and the fre-
quency of CCR4+
CCR6+
Th and Treg cells in PBMCs, the
antibodies (Table 2) - including CD105(FITC), CD73
(FITC), CD90(FITC), CD34(FITC), CD45(FITC), CD14
(PE) and HLA-DR(FITC) for BMSCs; CCR4(PE-Cy7),
CD196(CCR6)(PE) and CD4(FITC) for CCR4+
CCR6+
Th
cells [29]; and CD4(FITC), CD25(APC) and Fox-P3(PE)
antibodies for Treg cells - were used according to the
manufacturers’ recommendations. BMSCs and PBMCs
marked with appropriate antibodies were measured with a
FACScan laser flow cytometry system (Becton Dickinson)
immediately. In each experiment, control staining with the
appropriate isotype monoclonal antibodies was included.
Results were expressed as the mean (frequency, %) ± SD.
Statistical analysis
Data are expressed as the mean ± SD, and the signifi-
cance of the results was determined using the unpaired
Student’s t test. The product-moment correlation coeffi-
cient was used to test the correlations between the sup-
pression ratios of BMSCs and the ratio of CCR4+
CCR6+
Th cells to Treg cells in peripheral blood. Statistical ana-
lysis was performed using the SPSS computer program
(SPSS Inc., Chicago, IL, USA). P < 0.05 was considered
statistically significant.
Results
Growth characteristics and cell viability of AS-BMSCs are
normal
To evaluate the biological properties of AS-BMSCs,
compared with those of HD-BMSCs, the studies for
growth characteristics, cell viability and multiple differ-
entiation potentials in vitro were performed. The
Table 1 Details regarding the formula for percentage inhibition in the present study
Experiment wells Adjusted wells Blank wells
Two-way MLR BMSCs + 2 HD-PBMCs BMSCs 2 HD-PBMCs
Allogeneic PBMC proliferation assay BMSCs + 1 HD-PBMC + PHA BMSCs 1 HD-PBMC + PHA
BMSC, bone marrow-derived mensenchymal stem cell; PBMC, peripheral blood mononuclear cell; HD-PBMC, peripheral blood mononuclear cell of healthy donor;
PHA, phytohemagglutinin; MLR, mixed PBMC reaction.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 4 of 15
AS-BMSC growth curves have the same tendency as
those for HD-BMSCs. The BMSC proliferation data of
these two groups at each day (1 to 12 days) were tested
by unpaired Student’s t test, and the statistical result
indicates that there was no statistically significant differ-
ence in BMSC growth characteristics between ASp and
HDs (HD1 and HD2) (P > 0.05, Student’s t test for inde-
pendent samples). Established cultures (12 days) of
BMSCs exhibited close, even equivalent, cell viability at
each point of time from 1 to 12 days, as determined by
cellular viability assays, and the difference of OD at 490
nm between ASp and HDs (HD1 and HD2) at each day
(1 to 12 days) was not also statistically significant (P >
0.05, Student’s t test for independent samples). The cul-
tures have similar purities: (QL [the lower point of inter-
quartile range], QU [the upper point of interquartile
range]) = (95%, 99%) for AS-BMSCs, (QL, QU) = (96%,
98%) for HD1-BMSCs and (QL, QU) = (96%, 99%) for
HD2-BMSCs.
Triple differentiation potentials of AS-BMSCs in vitro were
not changed
To explore whether the multiple differentiation poten-
tials of BMSCs in AS were abnormal, we investigate the
osteogenic, adipogenic and chondrogenic differentiation
potentials of AS-BMSCs and HD-BMSCs in the present
study. Obvious differentiated osteocytes and adipocytes
were detected as early as the 7th day after being induced
for osteogenic and adipogenic differentiation, and
obvious differentiated chondrocytes were seen at about
14 days since induction (Figure 1A to 1C).
There appeared to be two stages in the BMSC differen-
tiation process for both ASp and HDs. In the early stage,
only a few osteocytes, adipocytes and chondrocytes were
found within the undifferentiated BMSCs. Gradually, these
three kinds of cells increased; simultaneously, the cell’s
body got bigger and cytoplasm became more abundant
because, for example, osteocytes made closer contact, fat
vacuoles of adipocytes multiplied and grew bigger, and
chondrocytes began to gain many collagen fibers. In the
later stage, these three kinds of cells increased rapidly and
nearly predominated. For the adipocytes, osteocytes and
chondrocytes derived from BMSCs, the purities were (QL,
QU) = (90%, 97%), (QL, QU) = (91%, 96%) and (QL, QU) =
(88%, 95%) for ASp, (QL, QU) = (88%, 98%), (QL, QU) =
(90%, 97%) and (QL, QU) = (90%, 96%) for HD1, and (QL,
QU) = (86%, 95%), (QL, QU) = (89%, 98%) and (QL, QU) =
(92%, 97%) for HD2, respectively.
The calcium nodules were stained to present a red
color (Figure 1A1 to 1D1), after Alizarin Red staining
for calcium deposits of osteocytes was performed to
determine the mineralization of BMSCs. For the adipo-
genic differentiation, the mass fat vacuoles of adipocytes
were also stained to present a red color by Oil Red O
staining (Figure 1A3 to 1C3). The well-differentiated
chondrocytes were Alcian Blue-positive, and presented a
bright blue color after staining (Figure 1A4 to 1C4).
The ALP activity, normalized to DNA concentration, is
plotted in Figure 1E. The ALP activity (mean ± SD) was
644 ± 45 (mM p-nitrophenyl phosphate/minute per mg
DNA) for AS-BMSCs (n = 51), which is lower than the
655 ± 49 for HD1-BMSCs (n = 37) (P > 0.05) and the 646
± 51 for HD2-BMSCs (n = 12) (P > 0.05). All three values
were much higher than those of the baseline ALP for
BMSCs of ASp, HD1 and HD2 (85 ± 40, 88 ± 48 and 82 ±
13, respectively) (P < 0.001) in control medium without
the osteogenic factors. ALP staining was performed on the
14th day to investigate the maturity degree of osteocytes
in the groups of Asp, HD1 and HD2 (Figure 1A2 to 1C2).
Phenotype of bone marrow-derived mesenchymal
stem cells
The AS-BMSCs and HD-BMSCs were then examined
for typical MSC phenotypic surface markers. Flow
Table 2 Antibodies used to detect CCR4+
CCR6+
Th and Treg cells in PBMCs and phenotype BMSCs by flow cytometry
Antibody Isotype Clone/fluorochrome Concentration (μg/ml) Source
CD105 (ENG)a
Mouse IgG1 266/FITC 10 Becton Dickinson (Bedford, MA, USA)
CD73 (NT5E)a
Mouse IgG1 AD2/FITC 20 Becton Dickinson (Bedford, MA, USA)
CD90 (THY1)a
Mouse IgG1 5E10/FITC 1 Becton Dickinson (Bedford, MA, USA)
CD34a
Mouse IgG1 581/FITC 50 Southern Biotech (Birmingham, AL, USA)
CD45 (PTPRC)a
Mouse IgG1 HI30/FITC 10 Caltag (Burlingame, CA, USA)
CD14a
Mouse IgG1 61D3/PE 200 Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)
HLA-DRa
Mouse IgG2a L243/FITC 200 Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)
CD4b
Mouse IgG2b OKT4/FITC 12 eBioscience (San Diego, CA, USA)
CD25b
Mouse IgG1, BC96/APC 25 eBioscience (San Diego, CA, USA)
FOX-P3b
Mouse IgG1 236A/E7/PE 50 eBioscience (San Diego, CA, USA)
CCR4b
Mouse IgG1, 1G1/PE-Cy7 200 BD Pharmingen™ (Basel, Switzerland)
CCR6 (CD196)b
Mouse IgG1, 11A9/PE 200 BD Pharmingen™ (Basel, Switzerland)
a
Antibodies used to phenotype bone marrow-derived mensenchymal stem cells (BMSCs) by flow cytometry. b
Antibodies used to detect CCR4+
CCR6+
CD4+
T-
helper (Th) cells and forkhead box P3-positive regulatory T (Treg) cells by flow cytometry. PBMC, peripheral blood mononuclear cell.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 5 of 15
cytometric analysis showed that the AS-BMSCs and
HD-BMSCs (HD1-BMSCs and HD2-BMSCs) have the
same phenotypic surface markers, just as the typical
MSCs did. The samples all express high levels of the
surface markers CD105, CD73 and CD90, and lack
expression of CD45, CD34, CD14 and HLA-DR surface
molecules (Figure 2).
Decreased suppressive potential of AS-BMSCs on either
two-way MLR or PBMC proliferation stimulated with PHA
Under the condition that the proliferation characteris-
tics, cell viability, multiple-differentiation potentials and
surface markers of AS-BMSCs were normal, compared
with HD-BMSCs, the immunomodulation potential of
AS-BMSCs was evaluated in the present study. The
Figure 1 Bone marrow-derived mensenchymal stem cell triple differentiation potentials from ankylosing spondylitis patients and
healthy donors. (A), (B), (C) Morphological characteristics of bone marrow-derived mensenchymal stem cells (BMSCs) for osteogenic,
adipogenic and chondrogenic differentiation evaluated by the inverted phase contrast microscope; ankylosing spondylitis (AS)-BMSCs have the
same morphological properties as the HLA-B27-negative healthy donor (HD1)-BMSCs and HLA-B27-positive healthy donor (HD2)-BMSCs.
Osteocytes were stained for calcium deposition using Alizarin Red-S (A1, B1, C1: x400) and for alkaline phosphatase (ALP) with the Cell Alkaline
Phosphatase-S assay (A2, B2, C2: x200). Adipocytes were filled with many fat vacuoles, and Red Oil O was used to stain the fat vacuoles of
adipocytes (A3, B3, C3: x200). Chondroblast differentiation from BMSCs was identified with Alcian blue staining (A4, B4, C4: x200). (D) General
photographs of BMSCs for osteogenic differentiation, stained with Alizarin Red-S. (E) ALP activities of AS-BMSCs, HD1-BMSCs and HD2-BMSCs
were 644 ± 45, 655 ± 49 and 646 ± 51, respectively; differences not statistically significant (P > 0.05). Data presented as mean ± standard
deviation. MLR, mixed peripheral blood mononuclear cell reaction; PHA, phytohemagglutinin.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 6 of 15
effects of BMSCs from ASp (n = 51), HD1 (n = 37) and
HD2 (n = 12) on two-way MLR or PBMC proliferation
in the presence of PHA were evaluated by mixing
BMSCs and mixed PBMCs for two-way MLR, or by
PBMCs from a third healthy volunteer in the presence
of PHA for PBMC proliferation assay at five BMSC:
PBMC ratios of 1:20, 1:10, 1:5, 1:2 and 1:1, respectively.
Two-way mixed PBMC reaction
The differences of absorbance between 0 days and 5
days were not statistically significant for the allogeneic
PBMCs from a healthy volunteer (P = 0.351) and the
PBMCs from another unrelated healthy volunteer (P =
0.418) (Figure 3A1). For the mixed PBMCs, however,
the absorbance at 5 days was significantly higher than
the value at 0 days (P < 0.001, Figure 3A1). As shown in
Figure 3A2,A3, there was a statistically significant reduc-
tion in suppressive potential (% inhibition) of BMSCs
from ASp on two-way MLR at all five ratios, compared
with the percentage inhibition of HD-BMSCs (P <
0.001, Figure 3A2,A3).
Allogeneic PBMC proliferation assay
Similarly, when PBMC proliferation was elicited by
means of PHA, the addition of BMSCs from ASp also
produced a statistically significant decreased inhibitory
effect on PBMC proliferation (Figure 3B2,B3; P < 0.001,
Student’s t test for independent data), ranging from a
BMSC:PBMC ratio of 1:20 to 1:1. Additionally, the dif-
ferences of absorbance between 0 days and 5 days with-
out PHA were not significant (P = 0.223), while the
value for 5 days with PHA was significantly higher than
the value at 0 days (P < 0.001, Figure 3B1).
Furthermore, in either the MLR (Figure 3A3) or the
PBMC proliferation assay stimulated with PHA (Figure
3B3), the 3
H-TdR assay data suggested a significant
relationship between dose and suppression of immunor-
eactivity of BMSCs for ASp, HD1 and HD2. The MTT
Figure 2 Phenotyping of bone marrow-derived mensenchymal stem cells for typical mensenchymal stromal cell surface markers.
Single-parameter histograms for (A1) to (A3), (B1) to (B3), (C1) to (C3) individual mensenchymal stromal cell (MSC) markers and (A4) to (A7),
(B4) to (B7), (C4) to (C7) MSC exclusion markers, representative of samples from patients with ankylosing spondylitis (AS) and from healthy
donors (blue lines). Red lines indicate background fluorescence obtained with isotype control IgG. x axis, fluorescence intensity; y axis, cell
counts. BMSC, bone marrow-derived mensenchymal stem cell; HD1, HLA-B27-negative healthy donors; HD2, HLA-B27-positive healthy donors.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 7 of 15
assay also presented this phenomenon basically, but not
clearly.
Increased CCR4+
CCR6+
Th and decreased Treg
populations in peripheral blood of patients with AS
Recent studies have independently revealed enhanced
Th17 response and weakened Treg response in some
autoimmune diseases [38,39], so we also examined the
frequencies of CCR4+
CCR6+
Th and Treg cells in
PBMCs of ASp and HDs (Figure 4). The PBMCs from
ASp and HDs were examined for the subset popula-
tions using flow cytometry, defined as the percentages
of CCR4+
CCR6+
Th cells (CCR4/CCR6 double-posi-
tive) [32] and Treg cells (CD4/CD25/Fox-P3 triple-
positive) accounting for the total CD4-positive Th cells
(CCR4+
CCR6+
Th/Th, Treg/Th), CD3-positive T cells
(CCR4+
CCR6+
Th/T, Treg/T), lymphocytes (CCR4
+
CCR6+
Th/L, Treg/L), and peripheral blood mono-
nuclear cells (CCR4+
CCR6+
Th/PBMCs, Treg/PBMCs)
respectively. The proportions of Fox-P3-positive occu-
pying CD4/CD25 double-positive cells (Fox-P3+
/CD4
+
CD25+
) and PBMCs (Fox-P3+
/PBMCs) were also
tested. Compared with healthy donors (HD1 and
HD2), the CCR4+
CCR6+
Th population of ASp was
significantly increased (P < 0.001, Table 3 and Figure
5), whereas Treg cells and Fox-P3-positive cells were
found to be significantly decreased (P < 0.001,
Student’s t test for independent data, Table 3 and
Figure 5). There were no significant differences
between HD1 and HD2.
Figure 3 Reduced suppressive potential of bone marrow-derived mensenchymal stem cells of patients with ankylosing spondylitis.
(A1) Absorbance of mixed peripheral blood mononuclear cells (PBMCs) at 5 days (0.194 ± 0.038) was significantly higher than the value at 0
days (0.104 ± 0.023) (*P < 0.001), showing the significant mixed PBMC reaction. (A2), (A3) Compared with healthy donor (HD)-bone marrow-
derived mensenchymal stem cells (BMSCs), the decreased percentage inhibition of ankylosing spondylitis (AS)-BMSCs on two-way mixed
peripheral blood mononuclear cell reaction (MLR) at different ratios showed that suppressive potentials of AS-BMSCs were reduced (% inhibition
reduced, *P < 0.001). (B1) PBMCs derived from a healthy volunteer could proliferate significantly the presence of phytohemagglutinin (PHA) in
vitro (P < 0.001). (B2), (B3) Percentage inhibition of AS-BMSCs on PBMC proliferation induced by PHA was significantly lower than the values of
HD-BMSCs at varied BMSC:PBMC ratios of 1:20, 1:10, 1:5, 1:2 and 1:1 (% inhibition reduced, *P < 0.001). Data expressed as mean ± standard
deviation of triplicates of three separate experiments. (A2), (B2) and (A3), (B3) were performed by MTT assay and 3
H-TdR assay respectively. There
were no statistically significant differences of suppressive potentials between (A2), (A3) HLA-B27-negative healthy donor (HD1)-BMSCs and (B2),
(B3) HLA-B27-positive healthy donor (HD2)-BMSCs. OD, optical density.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 8 of 15
BMSCs of patients with AS-induced CCR4+
CCR6+
Th/Treg
imbalance
We performed the direct contact co-culture of BMSCs
and PBMCs to explore whether the reduced immuno-
modulation potential of AS-BMSCs altered the balance
of CCR4+
CCR6+
Th/Treg cells. The PBMCs were col-
lected to be assayed by flow cytometry for the CCR4
+
CCR6+
Th and Treg cells after co-culture with BMSCs
of ASp and HDs (HD1 and HD2) for 3 days. The per-
centages of Treg cells (0.63 ± 0.23%) and Fox-P3-posi-
tive cells (0.74 ± 0.11%) in PBMCs after co-culture with
AS-BMSCs for 3 days reduced significantly, whereas the
percentages of CCR4+
CCR6+
Th cells (1.87 ± 0.29%) in
PBMCs after co-culture with AS-BMSCs for 3 days
increased significantly, compared with these values of
groups, including 3-day HD1, 3-day HD2, 3-day control,
Figure 4 Representative plots of CCR4+
CCR6+
T-helper and regulatory T cells. Representative plots of peripheral circulating populations of
(A1) to (A3) CCR4+
CCR6+
T-helper (Th) cells (green) and (B1) to (B3) regulatory T (Treg) cells (red) in peripheral blood mononuclear cells
(PBMCs) of patients with ankylosing spondylitis (ASp) (A1, B1), HLA-B27-negative healthy donors (HD1) (A2, B2) and HLA-B27-positive healthy
donors (HD2) (A3, B3). FOX-P3, forkhead box P3; FSH, forward scatter-height; SSH, side scatter-height.
Table 3 Percentages of CCR4+
/6+
Th and Treg cells in appropriate cell subsets
CCR4+
/CCR6+
Th/Th CCR4+
/CCR6+
Th/T CCR4+
/CCR6+
Th/L Treg/Th Treg/T Treg/L Fox-P3+
/CD4+
CD25+
ASp 9.81 ± 0.62 7.69 ± 0.63 4.24 ± 0.56 2.82 ± 0.24 2.12 ± 0.23 1.23 ± 0.13 22.23 ± 5.13
HD1 5.51 ± 0.59 3.53 ± 0.56 2.24 ± 0.48 5.27 ± 0.28 4.13 ± 0.26 2.54 ± 0.15 32.54 ± 7.05
HD2 5.34 ± 0.52 3.33 ± 0.45 2.17 ± 0.37 5.31 ± 0.23 4.21 ± 0.19 2.64 ± 0.18 34.92 ± 6.71
Data presented as the percentage mean ± standard deviation. The differences for all percentages between patients with ankylosing spondylitis (ASp) and either
HLA-B27-negative healthy donors (HD1) or HLA-B27-positive healthy donors (HD2) were significant (P < 0.001, according to a two-tailed significant level of 0.05).
There were no significant differences between HD1 and HD2 (P > 0.05). Th, CD4+
T-helper cells; T, T lymphocytes; L, lymphocytes; Treg, forkhead box P3-positive
regulatory T cells.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 9 of 15
and 0 days (P < 0.001, Figure 6). Impressively, the ratio
of CCR4+
CCR6+
Th cells to Treg cells (CCR4+
CCR6+
Th/Treg) in PBMCs after co-culture with AS-BMSCs
for 3 days increased significantly (P < 0.001, Figure 6).
Negative correlations between percentages of CCR4
+
CCR6+
Th/Treg cells and the suppressive ratio of BMSCs
When examining data from all subjects tested, we
observed positive correlations between the percentage
inhibition of BMSCs (MLR) and the percentage inhibi-
tion of BMSCs (PHA) for all of the 51 ASp, 37 HD1
and 12 HD2. Interestingly, however, for all of the ASp
(Figure 7A), HD1 (Figure 7B) and HD2 (Figure 7C)
there were significantly negative correlations between
the ratios of CCR4+
CCR6+
Th cells to Treg cells in the
peripheral blood and either percentage inhibition of
BMSCs (MLR) or percentage inhibition of BMSCs
(PHA) at all five ratios (P < 0.01, respectively).
Discussion
In the present study, we found that AS-BMSCs showed
normal proliferation, cell viability, surface markers and
multiple differentiations characteristics, but significantly
reduced immunomodulation potential; also, the frequen-
cies of Treg and Fox-P3+
cells in AS-PBMCs decreased,
but CCR4+
CCR6+
Th cells increased. Moreover, the AS-
BMSCs induced the ratio of CCR4+
CCR6+
Th/Treg cell
imbalance when co-cultured with PBMCs. Additionally,
no differences were found between HD1 and HD2.
Impressively, the immunomodulation potential of
BMSCs has negative correlation with the ratios of
CCR4+
CCR6+
Th to Treg cells in peripheral blood.
Characteristic symptoms of AS are spinal stiffness,
ankylosis and syndesmophytes [1], which are explained
by spinal inflammation, structural damage, or both [40].
As the ankylosis of the spine or even spinal stiffness was
probably initiated by the heterotopic ossification of
osteoblasts, and most of these osteoblasts derived from
BMSCs [41,42], and, simultaneously, there were some
abnormalities with the biological properties, including
the multiple differentiation potentials in some autoim-
mune disorders, such as severe aplastic anemia [14], we
performed research to examine the biology properties of
AS-BMSCs. We did not, however, detect any abnormal-
ity about the biological characteristics of AS-BMSCs in
vitro, including the proliferation ability, cell viability,
morphological features, differentiation potentials and
surface markers. Especially, the activity of osteogenic
differentiation and mineralization capacity are totally
normal. In addition, Braun and colleagues reported that
immunohistological studies on sacroiliac joint biopsies
have shown cellular infiltrates, including T cells and
macrophages, and that TNFa is overexpressed in sacroi-
liac joints [43]. These events indicated that the endogen-
ous osteogenic differentiation potential of BMSCs may
be not the real murderer, which was thought to induce
MSCs to produce heterotopic ossification; the appropri-
ate cell activity and cytokine function [44] existing in
the internal environments, which maintain BMSCs in
vivo, may play a critical role in the process of BMSC
heterotopic ossification.
There appears to be a reciprocal relationship between
the development of Treg cells and Th17 cells. Recent
studies have independently revealed enhanced Th17
response and weakened Treg response in some autoim-
mune diseases [38,39], indicating an important role for
Th17/Treg imbalance in the pathogenesis of autoimmu-
nity. The present study revealed that the Th17/Treg
imbalance existed in the peripheral blood of ASp, sug-
gesting its potential role in the breakdown of immune
self-tolerance in AS. Moreover, the physiological fre-
quency of Fox-P3+
and Treg cells can suppress autoim-
mune disorders, but the reduction or even depletion of
Fox-P3+
cells could lead to induction of autoimmunity
by specific ablation of Treg cells in genetically targeted
mice [45], these results indicated that the reduction of
Treg cells probably enhanced the pathological process
of AS. The balance between Treg and Th17 cells is
dependent on the localized cytokine milieu including
levels of IL-2, IL-6 [46] and transforming growth factor
beta (TGFb) [47], and the differentiation of both Treg
and Th17 cells required TGFb, but depends on oppos-
ing activities: at low concentrations, TGFb synergizes
with IL-6 and IL-21 to promote IL-23R expression,
Figure 5 Percentages of CCR4+
CCR6+
T-helper, regulatory T
and Fox-P3-positive cells in peripheral blood mononuclear
cells. Statistical multiple bar graphs showing percentages of
increased CCR4+
CCR6+
T-helper (Th) cells, reduced regulatory T
(Treg) cells and reduced forkhead box P3 (Fox-P3)-positive cells in
the peripheral blood mononuclear cells (PBMCs) of patients with
ankylosing spondylitis (ASp), compared with values for healthy
donors (HLA-B27-negative healthy donors (HD1) and HLA-B27-
positive healthy donors (HD2)). *P < 0.001, Student’s t test for
independent data.
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 10 of 15
favoring Th17 cell differentiation, while high concentra-
tions of TGFb repress IL-23R expression and favor Fox-
P3+
Treg cells [48].
Rivino and colleagues reported that the combination
of CCR4 and CCR6 does not uniquely define Th17 cells;
it also demarcated an IL-10-producing population of T
cells [49]. There are several reasons why the Th17 cells
were defined with the combination of CCR4 and CCR6
in this study. At first, CCR4 had been shown to mark
skin-homing T cells [50], expression of which has been
associated with the ability of cells to traffic into periph-
eral tissues [51]; in addition, the percentage of CD4
+
/CCR4+
T cells showed significant positive correlations
with the Bath Ankylosing Spondylitis Disease Activity
Index in AS [52]. Furthermore, the findings of Napoli-
tani and colleagues provide a functional link between
CCR6 and IL-17 [32], which have been independently
associated with tissue pathology. CCR6 has been shown
to be involved in the recruitment of pathogenic T cells
in rheumatoid arthritis [53], experimental autoimmune
encephalitis [54] and psoriasis [55,56], and Th17 cells
are increasingly recognized as essential mediators of
those diseases [25,57-61]. Besides, just like CCR4, CCR6
also mediates T-cell homing to skin and mucosal tissues
[62], and its expression facilitates the recruitment of
both dendritic cells and T cells in different diseases [60].
These findings illustrated that the Th17 cells CCR4
+
CCR6+
were the most active and aggressive pathogenic
ones. Second, only a fraction of IL-10-producing CCR6+
T cells co-expresses CCR4 [49]. Finally, Hill Gaston and
colleagues reported increased frequency of IL-17-produ-
cing T cells in AS [33]; these findings were consistent
with our study’s results. Moreover, they did not detect
any differences in the frequency of IL-10-positive CD4+
T cells between patients with arthritis and control sub-
jects, and none of the IL-17-positive cells co-expressed
Figure 6 Ratios of Fox-P3/PBMCs, CCR4+
CCR6+
Th/PBMCs, Treg/PBMCs and CCR4+
CCR6+
Th/Treg. Peripheral blood mononuclear cells
(PBMCs) were collected to be assayed by flow cytometry for the CCR4+
CCR6+
T-helper (Th) cells, regulatory T (Treg) cells and forkhead box P3
(Fox-P3)-positive cells after co-culture with or without (3 day-control) ankylosing spondylitis (AS)-bone marrow-derived mensenchymal stem cells
(BMSCs) (3 day-ASp), HLA-B27-negative healthy donors (HD1)-BMSCs (3 day-HD1) or HLA-B27-positive healthy donors (HD2)-BMSCs (3 day-HD2)
for 72 hours. Statistical multiple bar graphs show that AS-BMSCs induced the ratio of CCR4+
CCR6+
Th/Treg imbalance via reducing Treg/PBMCs
but increasing CCR4+
CCR6+
Th/PBMCs; it also produced a significant reduction of Fox-P3-positive cells in PBMCs (*P < 0.001, Student’s t test for
independent data).
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 11 of 15
IL-10. This means that the increased frequency of IL-17-
producing T cells in AS was not compensated for by an
increased frequency of IL-10-producing cells.
In the present study, we failed to find any significant
differences between HLA-B27-negative and HLA-B27-
positive healthy donors, which were essentially the same
in all respects we had studied. These findings indicated
that HLA-B27-positivity may be not responsible for
those abnormalities of ASp. Inflammation is one impor-
tant link within the pathogenesis of AS [1], while few
studies reported whether inflammation be responsible
for the altered properties of AS. Rheumatoid arthritis is
a typical inflammatory disease, One study reported that
the number of IL-17+
Th cells and CD4+
CD25+
Treg
cells in the peripheral blood of patients with rheumatoid
arthritis is elevated compared with that of healthy indi-
viduals [33,63], whereas other studies suggest no differ-
ences between these two groups [64,65]. Two groups
have reported that peripheral blood Treg cells isolated
from patients with rheumatoid arthritis and from con-
trol individuals showed no difference in their ability to
suppress effector T-cell proliferation [38]. Another
group, however, reported a striking defect in the capa-
city of Treg cells from patients with rheumatoid arthritis
to suppress effector T-cell proliferation [66]. These
divergent results could reflect differences in the popula-
tions of patients, the methods used to purify Treg
and Th17 cells, or how the suppression assays were
performed.
Recently, a study indicated that an alteration in the
balance of Th1, Th2, Th17, and Treg cells contributes
to the development of experimental autoimmune
myastheia gravis, and that the administration of BMSCs
can ameliorate the severity and, in a process dependent
on the secretion of TGF-b, presenting to inhibit the pro-
liferation of antigen-specific T cells, normalize the distri-
bution of the four T-helper subsets and their
corresponding cytokines [67]. In vitro experiments have
shown that human MSCs can induce the generation of
CD4+
T-cell subsets displaying a regulatory phenotype
(Treg) [8,68]. These results demonstrated that adminis-
tration of BMSCs from healthy donors to ASp may be a
novelty therapeutic strategy for AS.
The imbalance of Th17/Treg cell subsets may contribute
to the inflammatory responses [69] and heterotopic ossifi-
cation of MSCs [44] in AS by secreting the proinflamma-
tory T-cell cytokines. There is therefore a potential
mechanism of AS that reduced the immunomodulation
Figure 7 Correlation analysis between CCR4+
CCR6+
Th/Treg ratio and immunomodulation potential of bone marrow-derived
mensenchymal stem cells. (A) All patients with ankylosing spondylitis (ASp), (B) HLA-B27-negative healthy donors (HD1) and (C) HLA-B27-
positive healthy donors (HD2) presented significantly negative correlations between the ratio of CCR4+
CCR6+
T-helper (Th) cells to regulatory T
(Treg) cells in the peripheral blood mononuclear cells (PBMCs) and percentage inhibition either from two-way mixed PBMC reaction (MLR)
(upper panel) or PBMC proliferation induced by phytohemagglutinin (PHA) (lower panel) at a bone marrow-derived mensenchymal stem cell
(BMSC):PBMC ratio of 1:10 (P < 0.01, respectively).
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 12 of 15
potential of BMSC induced CCR4+
CCR6+
Th/Treg imbal-
ance and led to excessive activation of T cells, and then to
the increased proinflammatory CCR4+
CCR6+
Th cells and
reduced Treg cells. Fox-P3+
cells compounded by the
synergistic actions of activated T-cell cytokines drive the
local BMSCs into both osteoblasts and osteoclasts at loca-
lized sites of inflammation, and then the induced BMSCs
result in syndesmophytes, fusion of the sacroiliac joint and
even spinal stiffness via heterotopic ossification. Finally,
AS occurs.
Increasing evidence suggests that MSCs might be a
suitable cell population for immunosuppressive therapy
in solid organ transplantation and may be strong candi-
dates for cell therapy against human autoimmune dis-
eases [70-72]. The advantages of MSCs are obvious:
they can be easily harvested from a multitude of tissues,
can be cultured to nearly unlimited extent, and have
very promising immunomodulation effects [73]. The
immunoregulatory function of BMSCs thus appears to
represent a promising strategy for cytotherapy of auto-
immune diseases, such as AS, which is central to human
health and disease, and provides novel insights into new
therapeutic interventions. The retinoic acid receptor-
alpha [74] could be another considered candidate for
the treatment of autoimmunity, because signaling
through a specific nuclear retinoic acid receptor can
favor the decision to adopt the Treg cell fate at the
expense of the Th17 cell fate. The further elucidation of
the precise mechanism may aid in the identification of
targets for future immunomodulatory therapy of AS.
Conclusions
The reduced immunomodulation potential of BMSCs
may be an initiating factor for AS pathogenesis, and
may play a novelty role in triggering the onset of AS via
inducing the CCR4+
CCR6+
Th/Treg cell subset imbal-
ance. BMSCs may therefore be an interesting therapeu-
tic target in AS, suggesting the use of BMSCs from HDs
in the disease.
Abbreviations
ALP: alkaline phosphatase; AS: ankylosing spondylitis; AS-BMSC: bone
marrow-derived mensenchymal stem cell of patient with AS; ASp: patients
with ankylosing spondylitis; AS-PBMC: peripheral blood mononuclear cell of
patient with AS; BMSC: bone marrow-derived mensenchymal stem cell; CPM:
counts per minute; DMEM: Dulbecco’s modified Eagle’s medium; FBS: fetal
bovine serum; Fox-P3: forkhead box P3; 3
H-TdR: 3
H-thymidine; HD: healthy
donor; HD1: HLA-B27-negative healthy donors; HD2: HLA-B27-positive
healthy donors; HD-BMSC: bone marrow-derived mensenchymal stem cell of
healthy donor; HD-PBMC: peripheral blood mononuclear cell of healthy
donor; IL: interleukin; MLR: mixed peripheral blood mononuclear cell
reaction; MSC: mensenchymal stromal cell; MTT: methyl thiazolyl tetrazolium;
OD: optical density; PBMC: peripheral blood mononuclear cell; PBS:
phosphate-buffered saline; PCR: polymerase chain reaction; PHA:
phytohemagglutinin; QL: the lower point of interquartile range; QU: the
upper point of interquartile range; SD: standard deviation; TGFβ:
transforming growth factor beta; Th: T-helper; TNF: tumor necrosis factor;
Treg: regulatory T.
Acknowledgements
The authors thank Dr Xiaoping Wang at Sun Yat-sen University for assistance
with cell culturing, including BMSCs and PBMCs. They also thank Dr Jing Wei
for flow cytometry, and Wenfeng Xie and Hua Zeng for help with the
samples from ASp. The study was financially supported by the National
Natural Science Foundation of China (30973033), the Yat-sen Innovative
Talents Cultivation Program for Excellent Tutors (81000-3126203), the
Guangzhou Science and Technology Project (2008A1-E4011-9), the Natural
Science Foundation of Guangdong Province (9151008002000015), and the
Guangdong Provincial Science and Technology Project (2009B060300023).
Author details
1
Department of Othopaedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen
University, 107# Yanjiangxi Road, Guangzhou 510120, PR China. 2
Biotherapy
Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107#
Yanjiangxi Road, Guangzhou 510120, PR China. 3
Department of Othopaedics,
Guangdong Provincial People Hospital, 106# Zhongshan Road 2, Guangzhou
510080, PR China.
Authors’ contributions
RY, XL, YM and YT carried out the experimental work and the data collection
and interpretation. LH, KC and JY participated in the design and
coordination of experimental work, and the acquisition of data. MR and YW
participated in the study design, data collection, analysis of data and
preparation of the manuscript. PW and HS carried out the study design, the
analysis and interpretation of data and drafted the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 October 2010 Revised: 16 January 2011
Accepted: 21 February 2011 Published: 21 February 2011
References
1. Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369:1379-1390.
2. Penttinen MA, Heiskanen KM, Mohapatra R, DeLay ML, Colbert RA,
Sistonen L, Granfors K: Enhanced intracellular replication of Salmonella
enteritidis in HLA-B27-expressing human monocytic cells: dependency
on glutamic acid at position 45 in the B pocket of HLA-B27. Arthritis
Rheum 2004, 50:2255-2263.
3. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL,
Taylor A, Calin A, Wordsworth P: Susceptibility to ankylosing spondylitis in
twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997,
40:1823-1828.
4. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD:
Ankylosing spondylitis and HL-A 27. Lancet 1973, 1:904-907.
5. Paladini F, Belfiore F, Cocco E, Carcassi C, Cauli A, Vacca A, Fiorillo MT,
Mathieu A, Cascino I, Sorrentino R: HLA-E gene polymorphism associates
with ankylosing spondylitis in Sardinia. Arthritis Res Ther 2009, 11:R171.
6. Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ, Jin R, Zhou X,
Bradbury LA, Appleton LH, Davis JC, Diekman L, Doan T, Dowling A,
Duan R, Duncan EL, Farrar C, Hadler J, Harvey D, Karaderi T, Mogg R,
Pomeroy E, Pryce K, Taylor J, Savage L, Deloukas P, Kumanduri V,
Peltonen L, Ring SM, Whittaker P, et al: Genome-wide association study of
ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet
2010, 42:123-127.
7. Braun J, Tuszewski M, Ehlers S, Haberle J, Bollow M, Eggens U, Distler A,
Sieper J: Nested polymerase chain reaction strategy simultaneously
targeting DNA sequences of multiple bacterial species in inflammatory
joint diseases. II. Examination of sacroiliac and knee joint biopsies of
patients with spondyloarthropathies and other arthritides. J Rheumatol
1997, 24:1101-1105.
8. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 2005, 105:1815-1822.
9. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,
Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 13 of 15
lymphocyte proliferation induced by cellular or nonspecific mitogenic
stimuli. Blood 2002, 99:3838-3843.
10. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S,
Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal
stem cells suppress lymphocyte proliferation in vitro and prolong skin
graft survival in vivo. Exp Hematol 2002, 30:42-48.
11. Dazzi F, Marelli-Berg FM: Mesenchymal stem cells for graft-versus-host
disease: close encounters with T cells. Eur J Immunol 2008, 38:1479-1482.
12. Uccelli A, Moretta L, Pistoia V: Immunoregulatory function of
mesenchymal stem cells. Eur J Immunol 2006, 36:2566-2573.
13. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E,
Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A:
Mesenchymal stem cells ameliorate experimental autoimmune
encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
14. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A, Pozzi S,
Luchetti S, Frassoni F, Van Lint MT, Piaggio G: T-cell suppression mediated
by mesenchymal stem cells is deficient in patients with severe aplastic
anemia. Exp Hematol 2005, 33:819-827.
15. Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM,
Moretta A, Marconi M, Valli M, Novara F, Bonetti F, Zuffardi O, Maccario R,
Corazza GR, Locatelli F: Phenotypical/functional characterization of in
vitro-expanded mesenchymal stromal cells from patients with Crohn’s
disease. Cytotherapy 2009, 11:825-836.
16. Costantino CM, Baecher-Allan CM, Hafler DA: Human regulatory T cells
and autoimmunity. Eur J Immunol 2008, 38:921-924.
17. Ouyang W, Kolls JK, Zheng Y: The biological functions of T helper 17 cell
effector cytokines in inflammation. Immunity 2008, 28:454-467.
18. Mills KH: Induction, function and regulation of IL-17-producing T cells.
Eur J Immunol 2008, 38:2636-2649.
19. Romagnani S: Human Th17 cells. Arthritis Res Ther 2008, 10:206.
20. Vila J, Isaacs JD, Anderson AE: Regulatory T cells and autoimmunity. Curr
Opin Hematol 2009, 16:274-279.
21. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea AM, Tanaseanu C,
Dumitrache S, Otelea D, Tamsulea I, Tanaseanu S, Chitonu C, Paraschiv S,
Balteanu M, Stefanescu M, Matache C: Quantification and molecular
characterization of regulatory T cells in connective tissue diseases.
Autoimmunity 2009, 42:41-49.
22. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B,
Limburg PC, Kallenberg CG: Functional defect of circulating regulatory
CD4+
T cells in patients with Wegener’s granulomatosis in remission.
Arthritis Rheum 2007, 56:2080-2091.
23. Okumura A, Ishikawa T, Sato S, Yamauchi T, Oshima H, Ohashi T, Sato K,
Ayada M, Hotta N, Kakumu S: Deficiency of forkhead box P3 and
cytotoxic T-lymphocyte-associated antigen-4 gene expressions and
impaired suppressor function of CD4(+)CD25(+) T cells in patients with
autoimmune hepatitis. Hepatol Res 2008, 38:896-903.
24. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell
population that induces autoimmune inflammation. J Exp Med 2005,
201:233-240.
25. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T,
Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and antiinflammatory
roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med
2003, 198:1951-1957.
26. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R,
Drobyski WR: Absence of regulatory T-cell control of TH1 and TH17 cells
is responsible for the autoimmune-mediated pathology in chronic graft-
versus-host disease. Blood 2007, 110:3804-3813.
27. Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines
and the expanding diversity of effector T cell lineages. Annu Rev
Immunol 2007, 25:821-852.
28. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A,
Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA,
Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT,
Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP,
Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, et al:
Association scan of 14,500 nonsynonymous SNPs in four diseases
identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
29. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP:
Association of interleukin-23 receptor variants with ankylosing
spondylitis. Arthritis Rheum 2008, 58:1020-1025.
30. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ,
Vilches C, Gonzalez-Gay MA, Martin J: The IL23R Arg381Gln non-
synonymous polymorphism confers susceptibility to ankylosing
spondylitis. Ann Rheum Dis 2008, 67:1451-1454.
31. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W,
Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D,
Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the
critical cytokine for autoimmune inflammation of the brain. Nature 2003,
421:744-748.
32. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M,
Lanzavecchia A, Sallusto F, Napolitani G: Surface phenotype and antigenic
specificity of human interleukin 17-producing T helper memory cells.
Nat Immunol 2007, 8:639-646.
33. Shen H, Goodall JC, Hill Gaston JS: Frequency and phenotype of
peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid
arthritis. Arthritis Rheum 2009, 60:1647-1656.
34. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria
for ankylosing spondylitis. A proposal for modification of the New York
criteria. Arthritis Rheum 1984, 27:361-368.
35. Betz MW, Modi PC, Caccamese JF, Coletti DP, Sauk JJ, Fisher JP: Cyclic
acetal hydrogel system for bone marrow stromal cell encapsulation and
osteodifferentiation. J Biomed Mater Res A 2008, 86:662-670.
36. Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, Hwang JW, Jung JY, Kim SH,
Kang KS, Lee YS: Ras/MAP kinase pathways are involved in Ras specific
apoptosis induced by sodium butyrate. Cancer Lett 2005, 225:199-206.
37. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
38. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA,
Mauri C: Compromised function of regulatory T cells in rheumatoid
arthritis and reversal by anti-TNFα therapy. J Exp Med 2004, 200:277-285.
39. Boissier MC, Assier E, Falgarone G, Bessis N: Shifting the imbalance from
Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint
Bone Spine 2008, 75:373-375.
40. Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der
Heijde D: Association between radiographic damage of the spine and
spinal mobility for individual patients with ankylosing spondylitis: can
assessment of spinal mobility be a proxy for radiographic evaluation?
Ann Rheum Dis 2005, 64:988-994.
41. El Tamer MK, Reis RL: Progenitor and stem cells for bone and cartilage
regeneration. J Tissue Eng Regen Med 2009, 3:327-337.
42. Yang Y: Skeletal morphogenesis during embryonic development. Crit Rev
Eukaryot Gene Expr 2009, 19:197-218.
43. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U,
Distler A, Sieper J: Use of immunohistologic and in situ hybridization
techniques in the examination of sacroiliac joint biopsy specimens from
patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
44. Rifas L: T-cell cytokine induction of BMP-2 regulates human
mesenchymal stromal cell differentiation and mineralization. J Cell
Biochem 2006, 98:706-714.
45. Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P, Rudensky A,
Sparwasser T: Cutting edge: depletion of Foxp3+
cells leads to induction
of autoimmunity by specific ablation of regulatory T cells in genetically
targeted mice. J Immunol 2009, 183:7631-7634.
46. Kimura A, Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol
2010, 40:1830-1835.
47. Nistala K, Wedderburn LR: Th17 and regulatory T cells: rebalancing pro-
and anti-inflammatory forces in autoimmune arthritis. Rheumatology
(Oxford) 2009, 48:602-606.
48. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J,
Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3
inhibits T(H)17 cell differentiation by antagonizing RORgammat function.
Nature 2008, 453:236-240.
49. Rivino L, Gruarin P, Haringer B, Steinfelder S, Lozza L, Steckel B, Weick A,
Sugliano E, Jarrossay D, Kuhl AA, Loddenkemper C, Abrignani S, Sallusto F,
Lanzavecchia A, Geginat J: CCR6 is expressed on an IL-10-producing,
autoreactive memory T cell population with context-dependent
regulatory function. J Exp Med 2010, 207:565-577.
50. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP,
Warnke R, Ruffing N, Kassam N, Wu L, Butcher EC: The chemokine receptor
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 14 of 15
CCR4 in vascular recognition by cutaneous but not intestinal memory T
cells. Nature 1999, 400:776-780.
51. Baekkevold ES, Wurbel MA, Kivisakk P, Wain CM, Power CA, Haraldsen G,
Campbell JJ: A role for CCR4 in development of mature circulating
cutaneous T helper memory cell populations. J Exp Med 2005,
201:1045-1051.
52. Yang PT, Kasai H, Zhao LJ, Xiao WG, Tanabe F, Ito M: Increased CCR4
expression on circulating CD4(+) T cells in ankylosing spondylitis,
rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol
2004, 138:342-347.
53. Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, Koch AE: Role of
macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid
arthritis. Lab Invest 2003, 83:579-588.
54. Kohler RE, Caon AC, Willenborg DO, Clark-Lewis I, McColl SR: A role for
macrophage inflammatory protein-3 alpha/CC chemokine ligand 20 in
immune priming during T cell-mediated inflammation of the central
nervous system. J Immunol 2003, 170:6298-6306.
55. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E,
Catron D, Buchanan ME, Muller A, deWaal Malefyt R, Deng G, Orozco R,
Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A: Up-regulation of
macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine
receptor 6 in psoriasis. J Immunol 2000, 164:6621-6632.
56. Schaerli P, Britschgi M, Keller M, Steiner UC, Steinmann LS, Moser B,
Pichler WJ: Characterization of human T cells that regulate neutrophilic
skin inflammation. J Immunol 2004, 173:2151-2158.
57. Kikly K, Liu L, Na S, Sedgwick JD: The IL-23/Th(17) axis: therapeutic targets
for autoimmune inflammation. Curr Opin Immunol 2006, 18:670-675.
58. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction
of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003,
171:6173-6177.
59. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y: IL-17 production from
activated T cells is required for the spontaneous development of
destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc
Natl Acad Sci USA 2003, 100:5986-5990.
60. Cook DN, Prosser DM, Forster R, Zhang J, Kuklin NA, Abbondanzo SJ,
Niu XD, Chen SC, Manfra DJ, Wiekowski MT, Sullivan LM, Smith SR,
Greenberg HB, Narula SK, Lipp M, Lira SA: CCR6 mediates dendritic cell
localization, lymphocyte homeostasis, and immune responses in
mucosal tissue. Immunity 2000, 12:495-503.
61. Keller M, Spanou Z, Schaerli P, Britschgi M, Yawalkar N, Seitz M, Villiger PM,
Pichler WJ: T cell-regulated neutrophilic inflammation in
autoinflammatory diseases. J Immunol 2005, 175:7678-7686.
62. Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM: CC-
chemokine receptor 6 is expressed on diverse memory subsets of T
cells and determines responsiveness to macrophage inflammatory
protein 3 alpha. J Immunol 1999, 162:186-194.
63. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS: CD4(+)
CD25(+) regulatory T cells in rheumatoid arthritis: differences in the
presence, phenotype, and function between peripheral blood and
synovial fluid. Arthritis Rheum 2004, 50:2775-2785.
64. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P: Increased
numbers of circulating polyfunctional Th17 memory cells in patients
with seronegative spondylarthritides. Arthritis Rheum 2008, 58:2307-2317.
65. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR: Defects in CTLA-4 are
associated with abnormal regulatory T cell function in rheumatoid
arthritis. Proc Natl Acad Sci USA 2008, 105:19396-19401.
66. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM,
Lipsky PE: TNF downmodulates the function of human CD4+
CD25hi
T-
regulatory cells. Blood 2006, 108:253-261.
67. Kong QF, Sun B, Bai SS, Zhai DX, Wang GY, Liu YM, Zhang SJ, Li R, Zhao W,
Sun YY, Li N, Wang Q, Peng HS, Jin LH, Li HL: Administration of bone
marrow stromal cells ameliorates experimental autoimmune myasthenia
gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets
through the secretion of TGF-β. J Neuroimmunol 2009, 207:83-91.
68. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D,
Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F: Interaction of
human mesenchymal stem cells with cells involved in alloantigen-
specific immune response favors the differentiation of CD4+
T-cell
subsets expressing a regulatory/suppressive phenotype. Haematologica
2005, 90:516-525.
69. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B,
Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P,
Tonelli F, Maggi E, Romagnani S: Phenotypic and functional features of
human Th17 cells. J Exp Med 2007, 204:1849-1861.
70. Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F,
Yarmush ML: Immunomodulation of activated hepatic stellate cells by
mesenchymal stem cells. Biochem Biophys Res Commun 2007, 363:247-252.
71. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M: Treatment of
experimental arthritis by inducing immune tolerance with human
adipose-derived mesenchymal stem cells. Arthritis Rheum 2009,
60:1006-1019.
72. Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, Wang JH, Li R, Li HL:
BM stromal cells ameliorate experimental autoimmune myasthenia
gravis by altering the balance of Th cells through the secretion of IDO.
Eur J Immunol 2009, 39:800-809.
73. Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and
disease. Nat Rev Immunol 2008, 8:726-736.
74. Schambach F, Schupp M, Lazar MA, Reiner SL: Activation of retinoic acid
receptor-alpha favours regulatory T cell induction at the expense of IL-
17-secreting T helper cell differentiation. Eur J Immunol 2007,
37:2396-2399.
doi:10.1186/ar3257
Cite this article as: Wu et al.: Reduced immunomodulation potential of
bone marrow-derived mesenchymal stem cells induced CCR4+
CCR6+
Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Research
& Therapy 2011 13:R29.
Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit
Wu et al. Arthritis Research & Therapy 2011, 13:R29
http://arthritis-research.com/content/13/1/R29
Page 15 of 15
